Vivus (VVUS) 12.35 -0.425

Vivus, Inc.
(VVUS) 12.35 -0.425

Last Trade:	12.345	Day Range:	12.33 - 12.75
Trade Time:	08:02PM	52wk Range:	6.00 - 13.18
Prev. Close:	12.77	Market Cap:	1.1B
Open:	12.74	Div Yield:	0
Volume:	2254431	PE:
EPS:	-0.65

The Latest On VVUS

VIVUS Announces REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 1/17/12 6:47am

Jefferies Maintains Underperform, $3 PT on VIVUS 1/10/12 7:34am

Rodman & Renshaw Reiterates Perform, $10-$11 PT on VVUS 1/10/12 6:36am

Benzinga's Top Pre-Market Gainers 1/9/12 8:10am

VIVUS Provides Qnexa Regulatory Update; FDA Requests Removal of Contraindication for Women of Childbearing Potential 1/9/12 6:45am

Rodman & Renshaw Initiates VIVUS at Market Perform 1/5/12 7:39am

VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity 12/23/11 6:47am

End-of-Day Market Summary for December 22, 2011 12/22/11 4:16pm

Afternoon Movers; Markets Moved Higher 12/22/11 4:05pm

Leerink Swann Downgrades VIVUS to Market Perform 12/22/11 9:24am

Benzinga's Top Pre-Market Losers 12/22/11 8:17am

Benzinga's Top Downgrades 12/22/11 7:31am

VIVUS Announces REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 1/17/12

Jefferies Maintains Underperform, $3 PT on VIVUS 1/10/12

Rodman & Renshaw Reiterates Perform, $10-$11 PT on VVUS 1/10/12

Benzinga's Top Pre-Market Gainers 1/9/12

VIVUS Provides Qnexa Regulatory Update; FDA Requests Removal of Contraindication for Women of Childbearing Potential 1/9/12

Rodman & Renshaw Initiates VIVUS at Market Perform 1/5/12

VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity 12/23/11

End-of-Day Market Summary for December 22, 2011 12/22/11

Afternoon Movers; Markets Moved Higher 12/22/11

Leerink Swann Downgrades VIVUS to Market Perform 12/22/11

Benzinga's Top Pre-Market Losers 12/22/11

Benzinga's Top Downgrades 12/22/11

Biotech Stocks On the Move 12/5/11

Vivus Hopes FDA Approval Will Lead to Fat Profits 10/21/11

Financial Breakfast: Morning News Summary for September 13, 2011 9/13/11

Tuesday's NASDAQ Top Gainers 9/7/11

How to Profit from Exploding Government Healthcare Costs 7/28/11

Fifteen Health Care ETFs Trading Near 52-Week Highs 7/21/11

Twelve Health Care ETFs Trading Near 52-Week Highs 7/13/11

Biotech/Pharma Stocks Investor News Alert 7/6/11

Pre-Market Top Percentage Gainers and Losers (GLBC, LVLT, AMMD, ENDP, RAME, VVUS, BIIB, QUIK, MDVN, JACK, EDMC, GS, SINA) 4/11/11

How To Trade Biotech Stocks Better: Trading The NDAs (BIIB, AMGN, VVUS, GENZ, GLD) 3/4/11

Fast Money Pops & Drops, March 1st (CCL, BYD, LO, EMN, VVUS) 3/1/11

Trading Orexigen Therapeutics Terrible Results (OREX, ARNA, VVUS) 2/1/11

Jefferies Maintains Underperform, $3 PT on VIVUS 1/10/12

Rodman & Renshaw Reiterates Perform, $10-$11 PT on VVUS 1/10/12

Rodman & Renshaw Initiates VIVUS at Market Perform 1/5/12

End-of-Day Market Summary for December 22, 2011 12/22/11

Leerink Swann Downgrades VIVUS to Market Perform 12/22/11

Benzinga's Top Downgrades 12/22/11

Roth Capital Downgrades VIVUS to Neutral 12/22/11

UPDATE: Bank of America Raises Price Target on Vivus to $14 12/8/11

Bank of America Raises Po on Vivus to $14 12/8/11

Jefferies Maintains Underperform, $3 Target on VIVUS 12/5/11

Credit Suisse Initiating Coverage on Vivus 11/4/11

McNicoll, Lewis & Vlak Reiterates Vivus Buy, $16 PT 9/16/11

Trade VVUS
NOW!

Partner Headlines

8 Stocks Hitting New 52-Week Highs 2/7/12

Play TheStreet's FDA Drug-Approval Contest 1/23/12

Biotech Lessons Learned From JPM 2012 1/13/12

8 Stocks Rising on Unusual Volume 1/12/12

Vivus' Obesity Drug Label Modified - Analyst Blog 1/12/12

8 Stocks Rising on Unusual Volume 1/12/12

J.P. Morgan Biotech Confab Live Chat 1/9/12

6 Stocks Rising on Huge Volume 1/9/12

Press Releases

VIVUS to Present at the 9th Annual BIO Asia International Partnering Conference 1/26/12 GlobeNewswire Story

REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 1/17/12 Newswire Story

VIVUS Provides Qnexa Regulatory Update 1/9/12 Newswire Story

VIVUS to Present at the 2012 JP Morgan Healthcare Conference 1/4/12 Newswire Story

VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity 12/23/11 Newswire Story

VIVUS Reports Topline Findings From FORTRESS 12/21/11 Newswire Story

SEQUEL Trial Results for Qnexa® Published in AJCN Show 10% Sustained Weight Loss Over 2 Years 12/8/11 Newswire Story

Weight Loss and Effects on Diabetes with Qnexa Treatment Results Presented at the World Diabetes Congress 12/7/11 Newswire Story

Avanafil Data Presented at the European Society of Sexual Medicine Meeting 12/5/11 Newswire Story

VIVUS to Present at the Deutsche Bank BioFEST Conference 12/1/11 Newswire Story

15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting 11/14/11 Newswire Story

Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting 11/10/11 Newswire Story

Get the latest VVUS stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Vivus, Inc. stock price.

Vivus, Inc. by YCharts

Vivus (VVUS) 12.35 -0.425

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On VVUS

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social